

VIACELL INC  
Form 8-K  
November 02, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
THE SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): September 30, 2006  
VIACELL, INC.**

(Exact name of registrant as specified in its charter)

Delaware

000-51110

04-3244816

(State or other jurisdiction  
of incorporation or organization)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

245 First Street, Cambridge, Massachusetts 02142

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (617) 914-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**TABLE OF CONTENTS**

Item 2.02. Results of Operations and Financial Condition

Item 9.01 Financial Statements and Exhibits.

SIGNATURE

EXHIBIT LIST

Ex-99.1 Press Release

---

**Table of Contents**

**Item 2.02. Results of Operations and Financial Condition**

On November 2, 2006, ViaCell, Inc. issued a press release announcing its results of operations and financial condition for the third quarter of 2006. The press release attached as Exhibit 99.1 includes information with respect to ViaCell's pro forma basic and diluted net loss per common share in the first nine months of 2005. These are non-GAAP financial measures. These non-GAAP financial measures are utilized by the Company's management to gain an understanding of the Company's comparative financial performance. Management believes that these non-GAAP financial measures are useful because they include all outstanding shares of the Company, whether common or preferred, in the calculation of basic and diluted earnings per share. The presentation of this information is not meant to be considered in isolation or as a substitute for GAAP financial measures.

The information furnished herewith pursuant to Item 2.02 of this Current Report shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press release issued by ViaCell, Inc. dated November 2, 2006.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VIACELL, INC.

Date: November 2, 2006

By: /s/ Anne Marie Cook

Name: Anne Marie Cook

Title: General Counsel and Senior Vice  
President, Business and Corporate  
Development

**Table of Contents**

**EXHIBIT LIST**

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
99.1	Press release issued by ViaCell, Inc. dated November 2, 2006